ZSZhi-Jun Sun

Zhi-Jun Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhi-Jun Sun has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling

    by Bradford Hall, Hideyuki Nakashima, Zhi-Jun Sun, Yuki Sato, Yansong Bian, Syed R Husain, Raj K Puri, Ashok B Kulkarni

    Background: The sixth leading class of cancer worldwide is head and neck cancer, which typically arise within the squamous epithelium of the oral mucosa. Human head and neck squamous cell carcinoma (HNSCC) is known to be difficult to treat and has only a 50% five-year survival rate. With HNSCC, novel therapeutics are needed along with a means of rapidly screening anti-cancer agents in vivo, such as mouse models. Methods: In order to develop new animal models of cancer to test safety and efficacy of novel therapeutic agents for human HNSCC, tumors resembling clinical cases of human HNSCC were induced in the head and neck epithelium of a genetically engineered mouse model. This mouse model was generated by conditional deletion of two tumor suppressors, Transforming Growth Factor-β Receptor 1 (TGFβRI) and Phosphatase and Tensin homolog (PTEN), in the oral epithelium. We discovered that the tumors derived from these Tgfbr1/Pten double conditional knockout (2cKO) mice over-expressed IL-13Rα2, a high affinity receptor for IL-13 that can function as a tumor antigen. To demonstrate a proof-of-concept that targeted therapy against IL-13Rα2 expression would have any antitumor efficacy in this spontaneous tumor model, these mice were treated systemically with IL-13-PE, a recombinant immunotoxin consisting of IL-13 fused to the Pseudomonas exotoxin A. Results: Tgfbr1/Pten 2cKO mice when treated with IL-13-PE displayed significantly increased survival when compared to the untreated control mice. The untreated mice exhibited weight loss, particularly with the rapid onset of tongue tumors, but the treated mice gained weight while on IL-13-PE therapy and showed no clinical signs of toxicity due to the immunotoxin. Expression of IL-13Rα2 in tumors was significantly decreased with IL-13-PE treatment as compared to the controls and the number of myeloid-derived suppressor cells (MDSC) was also significantly reduced in the spleens of the IL-13-PE treated mice. Conclusions: Our study demonstrates that the Tgfbr1/Pten 2cKO mouse model of human HNSCC is a useful model for assessing antitumor activity of new cancer therapeutic agents, and that IL-13-PE has therapeutic potential to treat human head and neck cancer.


  • LMO2 promotes angiogenesis probably by up‐regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangioma

    by Zhi‐Jun Sun, Yu Cai, Gang Chen, Rong Wang, Jun Jia, Xin‐Ming Chen, Li‐Wu Zheng, Yi‐Fang Zhao

    Sun Z‐J, Cai Y, Chen G, Wang R, Jia J, Chen X‐M, Zheng L‐W & Zhao Y‐F (2010)Histopathology57, 622–632 LMO2 promotes angiogenesis probably by up‐regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangiomaAims: Infantile haemangiomas (IHs) are common benign vascular tumours distinctive for their perinatal presentation, rapid growth during the first year of life and subsequent slow involution. Recent research has indicated that endothelial cells of haemangiomas express LIM‐only protein 2 (LMO2). The aim of this study was to investigate the role of LMO2 in the pathogenesis of IHs was investigated.Methods and results: Immunoreactivity of LMO2 was assessed in specimens of 19 IH. Stable transfection of LMO2 into human endothelial cell lines (EAhy926) was performed to evaluate the role of LMO2 in terms of the change in cell proliferation, cell cycle and cell migration as well as the expression level of angiogenic factors. Immunoreactivity for LMO2 was detected in all IH specimens, specifically in the nucleus of the endothelial cells. The intensity of LMO2 immunostaining decreased significantly from proliferative to involuting stages. Furthermore, the overexpression of LMO2 enhanced the proliferation and migration of the endothelial cells and promoted G0/G1–S‐phase transitionin vitro, together with an up‐regulation of bFGF expression.Conclusions: LMO2 probably promotes angiogenesis by up‐regulation of bFGF expression and thereby consequently influences progression of IH.


  • Aneurysmal Bone Cysts of the Jaws: Analysis of 17 Cases

    by Zhi-Jun Sun, Yi-Fang Zhao, Rui-Li Yang, Roger A. Zwahlen


  • Epithelioid angiomatous nodule of head and neck

    by Zhi-Jun Sun, Yu Cai, Yi-Fang Zhao, Xiang Hu, Wei Zhang, Xin-Ming Chen, Fernand Mac-Moune Lai


  • Desmoplastic ameloblastoma – A review

    by Zhi-Jun Sun, Yan-Ru Wu, Ning Cheng, Roger A Zwahlen, Yi-Fang Zhao


  • Central giant cell granuloma of the jaws: clinical and radiological evaluation of 22 cases

    by Zhi-Jun Sun, Yu Cai, Roger A. Zwahlen, Yun-Fei Zheng, Shi-Ping Wang, Yi-Fang Zhao

    Objective The objective was to investigate the clinical and radiological characteristics of central giant cell granulomas (CGCGs) of the jaws. Methods A retrospective analysis of a 20-year database was performed regarding both clinical and radiological features of 22 patients affected with CGCGs of the jaws. Results Fourteen women and 8 men were included with the age range of 7–81 years (mean 31.7 years). Among the 22 lesions, 16 were located in the mandible and 6 in the maxilla. Painless swelling was the most common clinical feature in 18 of all cases. Limited mouth opening was noted in 2 patients where the lesions involved the condyle. Radiographically, 13 lesions were homogeneously osteolytic and 9 lesions were trabeculated. Fifteen lesions were unilocular and 14 lesions presented with well-defined but not sclerotic margins. CT images in 5 patients clearly showed the trabeculation within the lesions. The follow-up ranged from 1.5 to 11 years with a mean period of 5 years. Three out of 9 aggressive and 1 out of 13 nonaggressive lesions developed recurrence. Conclusions Diagnosis of CGCGs of the jaws depends on both correct interpretation of clinical, radiographic and pathological data. Differentiation between aggressive and nonaggressive CGCGs should be considered to improve individual treatment planning.


  • Review Article: Aneurysmal Bone Cysts of the Jaws

    by Z.J. Sun, H.L. Sun, R.L. Yang, R.A. Zwahlen, Y.F. Zhao

    Aneurysmal bone cyst (ABC) is a osteolytic bone lesion that rarely involves the jaws. To date, a total of 92 cases of JABCs have been described in detail in English literature. They prevalently occur in the first 2 decades (72.8%) with slight female predilection. It affects the mandible more often (68.5%) with a predominant location in the mandibular ramus (31.3%) and its posterior regions (20.4%). A painless (54.7%) or painful (43.2%) bone swelling is the most frequent clinical sign. Radiologically 93.8% of the lesions present as a radiolucency; in 69.4% multilocular in appearance. 15.2% of JABCs were secondary in nature, including 8 cases associated with fibrous dysplasia. The recurrence rate (13.3%) did not differ significantly when comparing the surgical technique (curettage, 15.2%; resection, 11.8%). JABCs are known for their different clinical and radiographic features, therefore often posing a diagnostic dilemma. Some JABC's may be secondary in nature. Careful curettage is considered to be suitable as treatment for JABCs.